Institution
Tehran University of Medical Sciences
Education•Tehran, Iran•
About: Tehran University of Medical Sciences is a education organization based out in Tehran, Iran. It is known for research contribution in the topics: Population & Cancer. The organization has 35661 authors who have published 57234 publications receiving 878523 citations. The organization is also known as: TUMS.
Papers published on a yearly basis
Papers
More filters
••
Spaulding Rehabilitation Hospital1, University of Göttingen2, University of New South Wales3, University of São Paulo4, Marche Polytechnic University5, University of Minho6, University of Milan7, Universidade Federal do Rio Grande do Sul8, Seoul National University9, Tehran University of Medical Sciences10, University of Oregon11, Virginia Tech12, University of Lyon13, City University of New York14, National Central University15, National Institute of Mental Health and Neurosciences16, Mackenzie Presbyterian University17
TL;DR: It is critical that a global or local effort is organized to pursue definite evidence to either approve and regulate or restrict the use of tDCS in clinical practice on the basis of adequate randomized controlled treatment trials.
Abstract: The field of transcranial electrical stimulation (tES) has experienced significant growth in the past 15 years. One of the tES techniques leading this increased interest is transcranial direct current stimulation (tDCS). Significant research efforts have been devoted to determining the clinical potential of tDCS in humans. Despite the promising results obtained with tDCS in basic and clinical neuroscience, further progress has been impeded by a lack of clarity on international regulatory pathways. We therefore convened a group of research and clinician experts on tDCS to review the research and clinical use of tDCS. In this report, we review the regulatory status of tDCS, and we summarize the results according to research, off-label and compassionate use of tDCS in the following countries: Australia, Brazil, France, Germany, India, Iran, Italy, Portugal, South Korea, Taiwan and United States. Research use, off label treatment and compassionate use of tDCS are employed in most of the countries reviewed in this study. It is critical that a global or local effort is organized to pursue definite evidence to either approve and regulate or restrict the use of tDCS in clinical practice on the basis of adequate randomized controlled treatment trials.
218 citations
••
TL;DR: High-dose ascorbic acid may be considered as an effective and safe adjuvant therapy in surgical critically ill patients with septic shock and the most effective dose and the best time for its administration should be determined in future studies.
Abstract: Objective: Effects of ascorbic acid on hemodynamic parameters of septic shock were evaluated in nonsurgical critically ill patients in limited previous studies. In this study, the effect of high-dose ascorbic acid on vasopressor drug requirement was evaluated in surgical critically ill patients with septic shock. Methods: Patients with septic shock who required a vasopressor drug to maintain mean arterial pressure >65 mmHg were assigned to receive either 25 mg/kg intravenous ascorbic acid every 6 h or matching placebo for 72 h. Vasopressor dose and duration were considered as the primary outcomes. Duration of Intensive Care Unit (ICU) stay and 28-day mortality has been defined as secondary outcomes. Findings: During the study period, 28 patients (14 in each group) completed the trial. Mean dose of norepinephrine during the study period (7.44 ± 3.65 vs. 13.79 ± 6.48 mcg/min, P = 0.004) and duration of norepinephrine administration (49.64 ± 25.67 vs. 71.57 ± 1.60 h, P = 0.007) were significantly lower in the ascorbic acid than the placebo group. No statistically significant difference was detected between the groups regarding the length of ICU stay. However, 28-day mortality was significantly lower in the ascorbic acid than the placebo group (14.28% vs. 64.28%, respectively; P = 0.009). Conclusion: High-dose ascorbic acid may be considered as an effective and safe adjuvant therapy in surgical critically ill patients with septic shock. The most effective dose of ascorbic acid and the best time for its administration should be determined in future studies.
218 citations
••
TL;DR: Quantification analysis of scaffolds on day 5 confirmed that, tissue engineered scaffolds with increased amount of angiogenesis number, granulation tissue area, fibroblast number, and decreased epithelial gap can be more effective compared to GT/PCL/Cur nanofibers.
216 citations
••
TL;DR: The air of patient rooms with confirmed COVID-19 in the largest hospital in Iran, on March 17, 2020, was investigated and all air samples were negative, however, it is suggested further in vivo experiments should be conducted using actual patient cough, sneeze and breath aerosols to show the possibility of generation of the airborne size carrier aerosol and the viability fraction of the embedded virus in those carrier aerosols.
216 citations
••
TL;DR: Heparin seems to be a safe and effective anti-inflammatory agent; although it is shown that heparin can decrease the level of inflammatory biomarkers and improves patient conditions, still more data from larger rigorously designed studies are needed to support use ofheparin as an anti- inflammatory agent in clinical setting.
Abstract: Background. Heparin, used clinically as an anticoagulant, also has anti-inflammatory properties. The purpose of this systematic review was to provide a comprehensive review regarding the efficacy and safety of heparin and its derivatives as anti-inflammatory agents. Methods. We searched the following databases up to March 2012: Pub Med, Scopus, Web of Science, Ovid, Elsevier, and Google Scholar using combination of Mesh terms. Randomized Clinical Trials (RCTs) and trials with quasi-experimental design in clinical setting published in English were included. Quality assessments of RCTs were performed using Jadad score and Consolidated Standards of Reporting Trials (CONSORT) checklist. Results. A total of 280 relevant studies were reviewed and 57 studies met the inclusion criteria. Among them 48 studies were RCTs. About 65% of articles had score of 3 and higher according to Jadad score. Twelve studies had a quality score > 40% according to CONSORT items. Asthma (n = 7), inflammatory bowel disease (n = 5), cardiopulmonary bypass (n = 8), and cataract surgery (n = 6) were the most studied disease condition. Forty studies use unfractionated heparin (UFH) for intervention; the remaining studies use low molecular weight heparin (LMWH). Conclusion. Despite the conflicting results, heparin seems to be a safe and effective anti-inflammatory agent; although it is shown that heparin can decrease the level of inflammatory biomarkers and improves patient conditions, still more data from larger rigorously designed studies are needed to support use of heparin as an anti-inflammatory agent in clinical setting. However, because of the association between inflammation, atherogenesis, thrombogenesis, and cell proliferation, heparin and related compounds with pleiotropic effects may have greater therapeutic efficacy than compounds acting against a single target.
216 citations
Authors
Showing all 35946 results
Name | H-index | Papers | Citations |
---|---|---|---|
Graeme J. Hankey | 137 | 844 | 143373 |
Paul D.P. Pharoah | 130 | 794 | 71338 |
Jerome Ritz | 120 | 644 | 47987 |
Reza Malekzadeh | 118 | 900 | 139272 |
Robert N. Weinreb | 117 | 1124 | 59101 |
Javad Parvizi | 111 | 969 | 51075 |
Omid C. Farokhzad | 110 | 329 | 64226 |
Ali Mohammadi | 106 | 1149 | 54596 |
Alexander R. Vaccaro | 102 | 1179 | 39346 |
John R. Speakman | 95 | 667 | 34484 |
Philip J. Devereaux | 94 | 443 | 110428 |
Rafael Lozano | 94 | 265 | 126513 |
Mohammad Abdollahi | 90 | 1045 | 35531 |
Ingmar Skoog | 89 | 458 | 28998 |
Morteza Mahmoudi | 83 | 334 | 26229 |